Suspension of trading

ETFs SpringWorks Therapeutics, Inc.

SWTX

US85205L1070

Pharmaceuticals

Delayed Nasdaq 16:00:00 2025-06-30 EDT			5-day change	1st Jan Change
46.99 ^USD	+0.02%		-.--%	-

12-15	Immunome jumps after promising results for its desmoid tumor treatment
12-01	Tyra Bioscience Appoints Bhavesh Ashar as Chief Operating Officer	MT

SpringWorks Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer. The Company developed and is commercializing OGSIVEO (nirogacestat) as a Food and Drug Administration (FDA)-approved medicine for adults with desmoid tumors and GOMEKLI (mirdametinib) as an FDA-approved medicine for both adults and children with neurofibromatosis type I associated plexiform neurofibromas (NF1-PN). It is also advancing a diverse portfolio of novel targeted therapy product candidates for patients with both solid tumors and hematological cancers. Brimarafenib is an investigational oral, small molecule, next-generation RAF dimer inhibitor that the Company is advancing in the clinic. SW-682 is an investigational oral, small molecule TEA Domain (TEAD), inhibitor that is evaluating in Hippo-mutant solid tumors. SW-3431 is an investigational, potentially first-in-class, small molecule activator of Protein Phosphotase 2A (PP2A), complexes.

Employees

368

Sector

Pharmaceuticals

More about the company